Nabriva Therapeutics Us, Inc

XENLETA

Manufacturer:

Nabriva Therapeutics Us, Inc

Xenleta HCPCS:

J0691

HCPCS Code Descriptor:

Injection, lefamulin, 1 mg

Category:

J Code

Xenleta NDCs:

72000-0120-06

Primary Type:

Antibiotic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

72000-0120-06

About Xenleta:

XENLETA is an Antibiotic drug manufactured by Nabriva Therapeutics Us, Inc and administered via the Intravenous route of administration. The J Code: J0691 is aligned to the drug XENLETA.

ACCESS PRICING AND MORE BY REGISTERING

J0691 Added Date:

July 1, 2020

J0691 Effective Date:

January 1, 2023

J0691 Termination Date:

HCPCS Active

Xenleta billing and coding information can be found through Nabriva Therapeutics Us, Inc at the link below:
Xenleta patient assistance information can be found through NA at the URL: https://www.xenleta.com/access-support
XENLETA prescribing information can be found at the link below:
Information regarding XENLETA’s side effects can be found at MedlinePlus